[Treatment of peptic ulcer with histamine H2 receptor antagonists].
Histamine H2-receptor antagonists (Burimamide, Metiamide and Cimetidine as the most recent generation) may drastically inhibit gastric acid secretion stimulated by histamine, pentagastrin, insulin, 2-deoxyglucose or an intragastrically instilled meal, respectively. This inhibitory action may explain the beneficial effects of H2-antagonists in the treatment of active peptic ulceration. On Cimetidine administered at a usual dosage over a 4--6 week period, serious side-effects must not be expected. At present studies aim to establish a Cimetidine dosage which, on long-term treatment, may reduce ulcer recurrency.
D002049:Burimamide / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy; D005750:Gastric Juice / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008309:Mallory-Weiss Syndrome / Q000188:drug therapy; D008785:Metiamide / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy*; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D006635:Histamine H2 Antagonists; D008785:Metiamide; D002049:Burimamide
Behandlung des Ulcus pepticum mit Histamin-H2-Rezeptor-Antagonisten.